^
Association details:
| Biomarker: | MET-UBE2H fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma
Excerpt:
...a repeat liquid biopsy was performed, which showed an acquired MET-UBE2H fusion gene by next-generation sequencing...The disease progressed, so the patient was switched to crizotinib (250 mg twice daily)...She achieved a partial response and progression-free survival at more than 6.5 months...We presented the first case involving a patient with the MET-UBE2H fusion gene who experienced a dramatic and durable antitumor response to crizotinib after acquired resistance to EGFR-TKI.
DOI:
10.1016/j.jtho.2018.05.009
